EHA 2021 | Phase I trial of donor-derived CD7 CAR T-cells for T-ALL
Jing Pan, MD, Beijing Boren Hospital, Beijing, China, discusses the findings of a Phase I trial of donor-derived CD7 chimeric antigen receptor (CAR) T-cells in patients with relapsed refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL). Of 20 patients enrolled in the trial 12 received CAR T-cells derived from previous hematopoietic stem cell transplant and 8 patents received CAR T-cells derived from fresh haplo-identical donors. 95% of patients responded to the therapy with 90% of patients achieving a complete remission. Of the 19 responders, 7 went on to receive stem cell transplantation. Of 12 responders followed up at a median of 4.4 months, 9 remained measurable residual disease (MRD)-negative. Dr Pan discusses the rationale for the trial and comments on the key efficacy and safety findings, in particular highlighting the incidence of graft-versus-host disease (GvHD). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
